These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 28398198)

  • 1. Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance.
    Anantha RW; Simhadri S; Foo TK; Miao S; Liu J; Shen Z; Ganesan S; Xia B
    Elife; 2017 Apr; 6():. PubMed ID: 28398198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic steps of mammalian homologous repair with distinct mutagenic consequences.
    Stark JM; Pierce AJ; Oh J; Pastink A; Jasin M
    Mol Cell Biol; 2004 Nov; 24(21):9305-16. PubMed ID: 15485900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
    Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
    Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair.
    Chen CC; Kass EM; Yen WF; Ludwig T; Moynahan ME; Chaudhuri J; Jasin M
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):7665-7670. PubMed ID: 28659469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.
    Stecklein SR; Kumaraswamy E; Behbod F; Wang W; Chaguturu V; Harlan-Williams LM; Jensen RA
    Proc Natl Acad Sci U S A; 2012 Aug; 109(34):13650-5. PubMed ID: 22869732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression.
    Wang Y; Deng O; Feng Z; Du Z; Xiong X; Lai J; Yang X; Xu M; Wang H; Taylor D; Yan C; Chen C; Difeo A; Ma Z; Zhang J
    Oncogene; 2016 Mar; 35(11):1363-72. PubMed ID: 26234677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
    Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
    Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of BRCA1 variants in double-strand break repair by homologous recombination and single-strand annealing.
    Towler WI; Zhang J; Ransburgh DJ; Toland AE; Ishioka C; Chiba N; Parvin JD
    Hum Mutat; 2013 Mar; 34(3):439-45. PubMed ID: 23161852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cancer therapy by PARP inhibitors].
    Seimiya H
    Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Analysis of BARD1 Missense Variants in Homology-Directed Repair of DNA Double Strand Breaks.
    Lee C; Banerjee T; Gillespie J; Ceravolo A; Parvinsmith MR; Starita LM; Fields S; Toland AE; Parvin JD
    Hum Mutat; 2015 Dec; 36(12):1205-14. PubMed ID: 26350354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
    Drost R; Dhillon KK; van der Gulden H; van der Heijden I; Brandsma I; Cruz C; Chondronasiou D; Castroviejo-Bermejo M; Boon U; Schut E; van der Burg E; Wientjens E; Pieterse M; Klijn C; Klarenbeek S; Loayza-Puch F; Elkon R; van Deemter L; Rottenberg S; van de Ven M; Dekkers DH; Demmers JA; van Gent DC; Agami R; Balmaña J; Serra V; Taniguchi T; Bouwman P; Jonkers J
    J Clin Invest; 2016 Aug; 126(8):2903-18. PubMed ID: 27454287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.
    Choi YE; Meghani K; Brault ME; Leclerc L; He YJ; Day TA; Elias KM; Drapkin R; Weinstock DM; Dao F; Shih KK; Matulonis U; Levine DA; Konstantinopoulos PA; Chowdhury D
    Cell Rep; 2016 Jan; 14(3):429-439. PubMed ID: 26774475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
    Chao OS; Goodman OB
    Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BRCA1 ubiquitin ligase and homologous recombination repair.
    Ohta T; Sato K; Wu W
    FEBS Lett; 2011 Sep; 585(18):2836-44. PubMed ID: 21570976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional variant analyses (FVAs) predict pathogenicity in the BRCA1 DNA double-strand break repair pathway.
    Loke J; Pearlman A; Upadhyay K; Tesfa L; Shao Y; Ostrer H
    Hum Mol Genet; 2015 Jun; 24(11):3030-7. PubMed ID: 25652403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells.
    Lu Q; Zhang FL; Lu DY; Shao ZM; Li DQ
    Cancer Med; 2019 Nov; 8(15):6730-6740. PubMed ID: 31512408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class I histone deacetylase inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage.
    Fukuda T; Wu W; Okada M; Maeda I; Kojima Y; Hayami R; Miyoshi Y; Tsugawa K; Ohta T
    Cancer Sci; 2015 Aug; 106(8):1050-6. PubMed ID: 26053117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high-throughput functional complementation assay for classification of BRCA1 missense variants.
    Bouwman P; van der Gulden H; van der Heijden I; Drost R; Klijn CN; Prasetyanti P; Pieterse M; Wientjens E; Seibler J; Hogervorst FB; Jonkers J
    Cancer Discov; 2013 Oct; 3(10):1142-55. PubMed ID: 23867111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.